Dianthus Therapeutics vs Edgewise Therapeutics

Dianthus Therapeutics (DNTH), health care, and Edgewise Therapeutics (EWTX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Key facts

Dianthus Therapeutics revenue
$2MFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

No live quote for Dianthus Therapeutics or Edgewise Therapeutics could be read just now, so their market value, valuation ratios and price changes show as —. The annual figures stand.

Dianthus Therapeutics vs Edgewise Therapeutics: every measure side by side
Measure Dianthus Therapeutics Edgewise Therapeutics
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap——
Revenue$2M—
Earnings-$162.3Mhigher-$167.8Mlower
Employees92lower133higher
Total assets$530.9Mlower$552.6Mhigher
Valuation
P/E——
P/S——
P/B——
Dividend yield——
Profitability
Operating margin-8739%—
Balance sheet
Net assets$493.4Mlower$522.3Mhigher
Total liabilities$37.5Mhigher$30.3Mlower
Total debt——
Cash on hand$51.1Mlower$61.1Mhigher
Price change
Today——
1 year——

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (1)

Dianthus Therapeutics only (1)

Edgewise Therapeutics only (1)

Percentages are each holding's share of that investor's reported portfolio (under "Both": Dianthus Therapeutics / Edgewise Therapeutics). Who owns DNTH · Who owns EWTX

Further comparisons

Learn

Questions and answers

Which superinvestors own both Dianthus Therapeutics and Edgewise Therapeutics?

In their latest 13F filings, Julian and Felix Baker holds both.

Cite this page

Funkfolio, “Dianthus Therapeutics vs Edgewise Therapeutics”, data as of 17 November 2026. https://funkfolio.com/compare/dnth-vs-ewtx

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.